Chronic Hepatitis B: Current and Future Treatment Options
Article first published online: 17 JAN 2012
2002 Pharmacotherapy Publications Inc.
Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
Volume 22, Issue 6, pages 721–737, June 2002
How to Cite
Rivkina, A. and Rybalov, S. (2002), Chronic Hepatitis B: Current and Future Treatment Options. Pharmacotherapy, 22: 721–737. doi: 10.1592/phco.22.9.721.34058
- Issue published online: 17 JAN 2012
- Article first published online: 17 JAN 2012
Hepatitis B, a major viral infection that can lead to cirrhosis and hepatocellular carcinoma, is the ninth most common cause of death worldwide. Prevention of hepatitis B virus transmission is key to reducing the spread of this serious condition. Management of chronic hepatitis B requires significant knowledge of approved pharmacotherapeutic agents and their limitations. Today, agents approved by the Food and Drug Administration for this infection are interferon-α-2b and lamivudine. Newer agents are being developed and hold promise: adefovir, famciclovir, ganciclovir, lobucavir, entecavir, emtricitabine, L-deoxythymidine, clevudine, a therapeutic vaccine, and thymosin α-1. Therapeutic options for managing hepatitis infection after liver transplantation are also evolving. These include hepatitis B immunoglobulin and nucleoside analogues.